Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Characterisation and Docking Studies of Thioxoquinoline Derivatives as Potential Anti-Alzheimer Agents

Author(s): Shalaka P. Naik, Chandavarkar Sachin*, Phadte Soniya, Naik Harishchandra, Sinari Venkatesh, Tawde Shilpa and Mamle Desai Shivlingarao

Volume 19, Issue 6, 2022

Published on: 17 August, 2022

Article ID: e130522204744 Pages: 11

DOI: 10.2174/1570163819666220513115542

Price: $65

Abstract

Background: Alzheimer’s Disease (AD) is related to the total loss of presynaptic neurotransmitters of the cholinergic system in regions of the brain related to memory. Approximately 15% of the population beyond the age of 65 years are suffering from dementia due to AD and the rate is rising exponentially with age.

Objective: The objective of this research was the synthesis of a series of 1-(4-substituted-2- thioxoquinolin-1(2H)-yl)-2-substituted ethanoneV (a-c(1-4)) by undergoing acetylation at the nitrogen of 4-hydroxyquinolin-2-(1H)-one and replacing its oxygen atom with sulphur moiety via the process of thionation. To carry out-docking studies of the title compounds were carried out using Molegro Virtual Docker (MVD-2013, 6.0) software and in-vitro screening of anti-alzheimer’s activity by Ellman assay method.

Methods: The synthesis of the title compounds was carried out via the sequential reaction from the initial dianilide to ring closure to the substituted quinoline-2-ones using polyphosphoric acid as a cyclising agent. These substituted quinoline-2-ones on thionation by phosphorous pentasulphide in aluminium trioxide gave quinoline-2-thiones and on further condensation with chloroacetyl chloride, they resulted in compounds with a leaving group. Nucleophilic substitution reaction of chloroacetylquinoline- 2-thiones with secondary amines resulted in the title compounds 1-(4-substituted-2- thioxoquinolin-1(2H)-yl)-2-substituted ethanone V(a-c(1-4)). The pharmacophore mapping of synthesized compounds was performed by using Molegro Virtual Docker (MVD-2013,6.0). The title compounds were tested for their in vitro anti-Alzheimer's activity using the Ellman assay method.

Results: All the synthesized compounds were characterized by IR, 1H NMR, 13C NMR, and Mass spectral data. Docking studies of all the synthesized compounds were carried out using a structural mechanism for the inhibition of CDK5-p25 by roscovitine, aloisine, and indirubin (PDB ID: 1UNG), showed favourable results, with compound (Vb3) showing a MolDock score of -85.9788 that was comparable to that of the active ligand (ALH_1288 [B]) with MolDock score of - 87.7609.

Conclusion: The synthesized derivatives possessed the potential to bind with some of the amino acid residues of the active site. Compound 2-(6-chloro-4-hydroxy-2-thioxoquinolin-1(2H)-yl-1-piperazin- 1-ethanone (Vb3) was found to be the most active among the synthesized derivatives, with IC50 values of 32 ± 0.1681. All the synthesized compounds showed potent to moderate activity in comparison to the reference standard donepezil.

Keywords: Anti-Alzheimer, thioxoquinoline, acetylcholinesterase, donepezil, ellman assay, docking studies.

Graphical Abstract

[1]
Bag S, Ghosh S, Tulsan R, et al. Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer’s disease. Bioorg Med Chem Lett 2013; 23(9): 2614-8.
[http://dx.doi.org/10.1016/j.bmcl.2013.02.103] [PMID: 23540646]
[2]
Chen X, Tikhonova IG, Decker M. Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors. Bioorg Med Chem 2011; 19(3): 1222-35.
[http://dx.doi.org/10.1016/j.bmc.2010.12.034] [PMID: 21232964]
[3]
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol 2016; 14(1): 101-15.
[http://dx.doi.org/10.2174/1570159X13666150716165726] [PMID: 26813123]
[4]
Uddin MS, Al Mamun A, Asaduzzaman M, et al. Spectrum of disease and prescription pattern for outpatients with neurological disorders: an empirical pilot study in Bangladesh. Ann Neurosci 2018; 25(1): 25-37.
[http://dx.doi.org/10.1159/000481812] [PMID: 29887680]
[5]
Uddin MS, Kabir MT, Jeandet P, et al. Novel anti-alzheimer’s therapeutic molecules targeting amyloid precursor protein processing. Oxid Med Cell Longev 2020; 2020: 7039138.
[http://dx.doi.org/10.1155/2020/7039138] [PMID: 32411333]
[6]
Naik S. MamleDesai S, Tari P, Hullolikar R, Rajadhyax A. Synthesis of 2-mercaptopyrimidylquinolin-2-(1H)-one derivatives as antibacterial and antitubercular agents. Indian J Heterocycl Chem 2015; 25: 55-60.
[7]
Rajadhyax A. MamleDesai S, Naik S, Tari P. Synthesis of 4-methoxy-1-phenylimethyl-3-[5-(phenyl/substitutedphenyl)-4, 5-dihydro-(1H)-pyrazol-3-ylpuinolin-2 (1H)-one derivatives as antibacterial agents. Indian J Heterocycl Chem 2015; 25: 173-6.
[8]
Reis M. MamleDesai S, Naik S, Fernandes J, Tari P. Synthesis and evaluation of 2-(4-methoxy-2-oxo-1-phenyl/methyl-1,2-dihydroqui- nolin-3-yl)-2-methyl-3-(phenyl/substitutedphenyl-amino) thiazolidin-4-one as antibacterial and anticancer agents. Indian J Chem 2016; 55B: 1254-8.
[9]
Priolkar RNS, Shingade S, Palkar M. MamleDesai S. Design, synthesis and characterization of novel linomide analogue and evaluation for anticancer activity. Curr Drug Discov Technol 2020; 17(2): 203-12.
[http://dx.doi.org/10.2174/1570163815666181008151037] [PMID: 30306874]
[10]
Olivia J, Akhemedjanova V, Angenot L, Balansad V. Screening of 14 alkaloids isolated from Halophyllum A. Juss for their cytotoxic properties. J Ethnopharmacol 2003; 105: 241-5.
[11]
Katagi MS, Mamledesai S, Bolakatti G, Fernandes J, Sujatha ML, Tari P. Design, synthesis, and characterization of novel class of 2-quinolon-3-oxime reactivators for acetylcholinesterase inhibited by organophosphorus compounds. Chem Data Collect 2020; 30: 100560.
[http://dx.doi.org/10.1016/j.cdc.2020:100560]
[12]
Dgachi Y, Sokolov O, Luzet V, et al. Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer’s disease therapy. Eur J Med Chem 2017; 126: 576-89.
[http://dx.doi.org/10.1016/j.ejmech.2016.11.050] [PMID: 27918993]
[13]
Fernández-Bachiller MI, Pérez C, González-Muñoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem 2010; 53(13): 4927-37.
[http://dx.doi.org/10.1021/jm100329q] [PMID: 20545360]
[14]
Soares AD. MamleDesai S, Tiwari P, Palkar MB, Shingade SG, Biradar B. synthesis of 6-substituted-4-hydroxy-1-(2-substitutedali- cyclicamino) acetyl) quinolin-2 (1H)-one derivatives and evaluation of their in vitro anticancer activity. Indian J Chem 2019; 58B: 1167-72.
[15]
Lolienkar M. MamleDesai S, Naik S, Katagi MS. Synthesis of Isoxazoloquinolin-2-ones and evaluation for their reactivation efficacy against diisopropyl fluorophosphate inhibited acetylcholinesterase. Indian J Heterocycl Chem 2017; 47(3): 1-4.
[16]
Polshettiwar V, Kaushik MP. A new, efficient and simple method for the thionation of ketones to thioketones using P4S10/Al2O3. Tetrahedron Lett 2004; 45(3): 6255-7.
[http://dx.doi.org/10.1016/j.tetlet.2004.06.091]
[17]
Vogel HG, Vogel HW. Analgesic, anti-inflammatory, and antipyretic activity. Drug discovery and evaluation Drug Discovery and Evaluation: Pharmacological Assays. Springer 1997; 1: pp. 318-9.
[http://dx.doi.org/10.1007/978-3-662-03333-3_8]
[18]
Palkar MB, Singhai AS, Ronad PM, et al. Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorg Med Chem 2014; 22(10): 2855-66.
[http://dx.doi.org/10.1016/j.bmc.2014.03.043] [PMID: 24751552]

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy